Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
3500 participants
OBSERVATIONAL
2022-11-08
2030-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Screen-detected Coeliac Disease, a Population Based Study
NCT01695681
Gluten-free Oats and Gastrointestinal Health in Coeliac Disease, Part 1
NCT02764931
Risk Factors for the Development of Celiac Disease in Genetically Predisposed Children
NCT04034303
Treatment of Screen-detected Celiac Disease
NCT01116505
Celiac Disease Genomic Environmental Microbiome and Metabolomic Study
NCT02061306
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In this study coeliac disease and dermatitis herpetiformis patients and healthy controls will be recruited. Genetic, clinical, immunological, micobiata and novel biomedical markers are compared between coeliac disease phenotypes and also controls and their prognostic value is assessed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Coeliac disease patients
Adult (18 years or over) patients with previous coeliac disease or dermatitis herpetiformis diagnosis
Genetic predisposition
Assessment of genetic predisposition to various celiac disease phenotypes. No intervention.
Healthy controls
500 adult (18 years or over) friends or non-related family members of coeliac disease or dermatitis herpetiformis patients participating in the study, no previous coeliac disease or dermatitis herpetiformis diagnosis. In addition 1000 controls will be included from Biobank
Genetic predisposition
Assessment of genetic predisposition to various celiac disease phenotypes. No intervention.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Genetic predisposition
Assessment of genetic predisposition to various celiac disease phenotypes. No intervention.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Cohort 3: friend or non-related family member of coeliac disease or dermatitis herpetiformis patient
Exclusion Criteria
* Cohorts 1 and 2: coeliac disease or dermatitis herpetiformis diagnosis not confirmed
* Cohort 3: coeliac disease or dermatitis herpetiformis diagnosis
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tampere University
OTHER
University of Helsinki
OTHER
University of Turku
OTHER
Oulu University Hospital
OTHER
University of Debrecen
OTHER
University of Trieste
OTHER
Oslo University Hospital
OTHER
Tampere University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Teea Salmi
Professor in Dermatology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tampere University Hospital
Tampere, , Finland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
R22088
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.